FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal

Biosimilar Supplement Review Goals Aim To Speed Approvals

 
• By Dean Rudge
  
Entrance to FDA headquarters in Maryland
BSUFA III covers the fiscal years 2023-27 • Source: Shutterstock

More from Biosimilars

More from Products